Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Biodesix (BDSX) Falls -68% in 30 Days After Q3 Miss and Guidance Cut

Biodesix (BDSX) Falls -68% in 30 Days After Q3 Miss and Guidance Cut

Key Takeaways

  • Biodesix shares declined roughly 68% over the 30 days ending in late November, falling from about $23.93 to approximately $7.74.
  • The move was driven almost entirely by a disappointing third-quarter 2026 earnings report released on November 5.
  • Quarterly revenue of $24.0 million missed analyst expectations, and management cut full-year 2026 revenue guidance to $101–$103 million from a prior range of $108–$114 million.
  • Shares plunged about 57% in a single session on November 6, dropping from $19.84 to $8.53.
  • Management attributed the shortfall to execution and timing issues—fewer contributing sales representatives, primary-care seasonality, and delayed development-services projects—rather than weakening demand.
  • Diagnostic testing revenue still grew 16% year over year on a 24% increase in test volumes, and several analysts trimmed price targets while retaining Buy ratings.

Understanding Biodesix (BDSX) and Its Market Position

Biodesix, Inc. is a diagnostics company focused on personalized, blood-based testing for lung disease. Headquartered in Louisville, Colorado, the company commercializes tests that help clinicians assess the risk of malignancy in suspicious lung nodules and guide treatment decisions after a lung cancer diagnosis. Its portfolio includes the Nodify XL2 and Nodify CDT lung nodule risk-assessment tests, as well as the GeneStrat and VeriStrat tests marketed under the IQLung testing strategy. Biodesix also operates a Development Services segment that provides diagnostic testing and consulting for biopharmaceutical and life-sciences companies. The company reported roughly 81% gross margin for 2025 and generated about 32% of its revenue from Medicare, underscoring the importance of payer reimbursement to its model. Investors follow BDSX for its exposure to lung-cancer diagnostics, its expanding sales force, and its path toward profitability.

Biodesix (BDSX) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, BDSX declined approximately 68%, from a closing price of about $23.93 on October 21 to roughly $7.74 in late November. The decline was not gradual: the stock fell about 57% in a single trading session on November 6, after the company reported third-quarter results and lowered its full-year outlook.

The last quarter tells a similar story of a sharp reset. Through much of August, September, and early October, the stock traded broadly in a $24–$30 range, reaching an intraday high near $31.97 in late September. From roughly $24 in mid-August, shares ended the period near $7.74, a decline of about 68% over the quarter. The multi-month gains that had built through 2026 were largely erased within a matter of days following the earnings release.

What Drove BDSX Stock Price in the Last 30 Days

The dominant catalyst was Biodesix's third-quarter 2026 earnings report on November 5. The company posted revenue of $24.0 million, below consensus estimates, and reduced its full-year 2026 revenue guidance to $101–$103 million from a prior range of $108–$114 million. Although the net loss per share of $0.75 was roughly in line with expectations and narrowed from $1.16 a year earlier, the revenue miss and guidance cut outweighed the improvement.

Chief Executive Officer Scott Hutton cited "execution and timing challenges," including fewer contributing sales representatives than planned—the company averaged 101 representatives during the quarter—higher turnover, a hiring pace that lagged attrition, greater-than-anticipated seasonality in primary care, and customer-delayed start dates for several development-services projects. Management emphasized that these factors reflected commercial execution rather than reduced demand, noting that diagnostic testing revenue grew 16% year over year on a 24% increase in test volumes. I also checked this using Tickeron’s AI Screener to compare the stock with peers in the diagnostics space.

The sharp repricing also triggered a wave of investor scrutiny. Multiple shareholder-rights law firms, including Kirby McInerney, Pomerantz, Levi & Korsinsky, and Johnson Fistel, announced investigations into potential securities-law claims following the drop. Analysts responded by trimming price targets—H.C. Wainwright lowered its target to $34 from $38, Lake Street to $30 from $40, and TD Cowen to $34 from $40—while generally maintaining Buy ratings.

What Drove BDSX Stock Performance Over the Last Quarter

For most of the quarter, BDSX benefited from a broader positive narrative around expanding reimbursement coverage, a growing sales organization, and progress toward adjusted EBITDA positivity, which the company first reached in the fourth quarter of 2025. The stock climbed through late summer and early autumn, reflecting optimism about increased test volumes and improving average selling prices for its lung diagnostic tests.

That momentum reversed abruptly when the third-quarter report revealed that commercial execution had lagged internal plans. The quarter's decline therefore reflects a convergence of factors: a revenue shortfall, a full-year guidance reduction, concern about sales-force attrition and hiring, and a subsequent wave of litigation-related headlines. The result was a repricing that brought shares from their highest levels of the year back toward single digits.

BDSX Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors will monitor whether Biodesix can rebuild its commercial capacity and return to its prior growth trajectory. Key factors include sales-representative hiring and retention, test-volume trends, average selling prices, and progress on development-services contracts. Reimbursement developments, particularly Medicare coverage and commercial payer decisions, remain central given the company's revenue concentration. Management has signaled priorities around expanding the sales force, automating care pathways, advancing digital diagnostics, and reaching profitability by the end of 2027. Any resolution of the shareholder investigations, updates to full-year guidance, and analyst revisions will also influence sentiment. From what I see, these elements will shape the path forward for BDSX. As always, the information above is provided for context and is not investment advice.

Exploring Tickeron’s AI Trading Bots for Market Insights

In my research process, I frequently review Tickeron’s AI Trading Bots to see how automated strategies are positioning across various tickers and sectors. The platform offers hundreds of bots with different approaches, timeframes, and risk profiles, which helps me cross-check ideas and understand broader market dynamics without replacing my own analysis. It is a useful supplement when evaluating names like BDSX alongside traditional fundamentals.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BDSX

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


BDSX in -6.53% downward trend, falling for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where BDSX declined for three days, in 275 of 305 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDSX as a result. In 77 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Aroon Indicator for BDSX entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +12.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 202 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.843) is normal, around the industry mean (67.298). P/E Ratio (-2.752) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. BDSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -10%. For the same Industry, the average monthly price growth was -17%, and the average quarterly price growth was 16%. VCYT experienced the highest price growth at 3%, while ADVB experienced the biggest fall at -35%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 15%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 50
SMR Rating: 78
Profit Risk Rating: 88
Seasonality Score: 24 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Industry
N/A
Address
919 West Dillon Road
Phone
+1 303 417-0500
Employees
334
Web
https://www.biodesix.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.